Prostate Cancer International is a
non-profit for 2012 as rated by Great NonProfits
Another breathless media release has announced enrollment of the first patient into a Phase II clinical trial of yet another new form of high-intensity, focused ultrasound (HIFU) in men with low-risk and favorable, intermediate-risk, localized prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment, Uncategorized | Tagged: focal, HIFU, high-intensity, trial, ultrasound | Leave a comment »
A major plenary presentation at the upcoming annual meeting of the American Urological Association (AUA) will provide data from a rather small French trial of high-intensity focused ultrasound (HIFU) in the focal management of localized prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment, Uncategorized | Tagged: ablation, focal, hemiablation, HIFU, high-intensity, outcome, ultrasound | Leave a comment »
For several years now, the Ahmed/Emberton-led research team in the United Kingdom (UK) has published the majority of the detailed outcomes data from treatment of men with localized prostate cancer using high-intensity focused ultrasound (HIFU). This group has now given us 5-year outcomes on a cohort of > 550 patients. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: complication, focused, HIFU, high-intensity, outcome, side effect, ultrasound | 13 Comments »
A new report provides data from a prospective, single-center, Phase II trial of high-intensity focused ultrasound (HIFU) in prostate cancer hemiablation as a form of focal therapy. The study was carried out in Belgium. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: focal, focused, hemiablation, HIFU, high-intensity, outcome, Treatment, ultrasound | 1 Comment »
For those able to access the February 2016 issue of the AUA News, it carries an interesting article outlining the U.S. Food and Drug Administration’s perspective on exactly why the agency decided to approve two forms of high-intensity focused ultrasound (HIFU) technology for the transrectal ablation of prostate tissue. … READ MORE …
Filed under: Management, Treatment | Tagged: approval, FDA, focuse, HIFU, high-intensity, ultrasound | 3 Comments »
A newly published paper in European Urology has provided us with data from one of the earliest, well-documented series of patients undergoing focal therapy of the index lesion from what is known to have been multifocal prostate cancer. … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: focal, HIFU, high-intensity, index, lesion, outcome, ukltrasound | 8 Comments »
As predicted, the U.S. Food and Drug Administration apparently approved the Ablatherm brand of equipment for high-intensity focused ultrasound (HIFU) on November 9 for “the ablation of prostate tissue.” … READ MORE …
Filed under: Uncategorized | Tagged: Ablatherm, approval, focused, HIFU, high-intensity, ultrasound | 2 Comments »
